State Street Corp Has $32.87 Million Position in Harrow, Inc. (NASDAQ:HROW)

State Street Corp raised its stake in Harrow, Inc. (NASDAQ:HROW - Free Report) by 2.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 730,973 shares of the company's stock after acquiring an additional 15,554 shares during the period. State Street Corp owned 2.06% of Harrow worth $32,865,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Janus Henderson Group PLC purchased a new position in shares of Harrow in the third quarter valued at $606,000. Braidwell LP grew its holdings in Harrow by 47.9% during the 3rd quarter. Braidwell LP now owns 439,638 shares of the company's stock valued at $19,766,000 after purchasing an additional 142,450 shares in the last quarter. Verition Fund Management LLC purchased a new position in Harrow in the third quarter valued at about $951,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Harrow in the 3rd quarter worth about $1,469,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Harrow during the 3rd quarter valued at approximately $338,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Price Performance

Shares of NASDAQ HROW traded down $0.21 during trading on Friday, reaching $34.22. The company had a trading volume of 554,342 shares, compared to its average volume of 503,364. The business's 50 day moving average price is $44.55 and its 200-day moving average price is $36.78. Harrow, Inc. has a 52 week low of $9.13 and a 52 week high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The stock has a market cap of $1.22 billion, a PE ratio of -36.40 and a beta of 0.69.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HROW. B. Riley reduced their price target on Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a research report on Wednesday, December 4th. Lake Street Capital increased their price objective on Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Friday, October 4th. Finally, Craig Hallum upped their price target on shares of Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research note on Friday, October 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.